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Abstract
Context: Anti-Mullerian hormone (AMH) was originally described in the context of
sexual differentiation in the male fetus but has gained prominence now as a marker of
ovarian reserve and fertility in females. In this mini-review, we offer an updated synopsis
on AMH and its clinical utility in pediatric patients.
Design and Results: A systematic search was undertaken for studies related to the
physiology of AMH, normative data, and clinical role in pediatrics. In males, AMH,
secreted by Sertoli cells, is found at high levels prenatally and throughout childhood
and declines with progression through puberty to overlap with levels in females. Thus,
serum AMH has clinical utility as a marker of testicular tissue in males with differences
in sexual development and cryptorchidism and in the evaluation of persistent Mullerian
duct syndrome. In females, serum AMH has been used as a predictive marker of
ovarian reserve and fertility, but prepubertal and adolescent AMH assessments need
to be interpreted cautiously. AMH is also a marker of tumor burden, progression, and
recurrence in germ cell tumors of the ovary.
Conclusions: AMH has widespread clinical diagnostic utility in pediatrics but interpretation
is often challenging and should be undertaken in the context of not only age and sex but
also developmental and pubertal stage of the child. Nonstandardized assays necessitate
the need for assay-specific normative data. The recognition of the role of AMH beyond
gonadal development and maturation may usher in novel diagnostic and therapeutic
applications that would further expand its utility in pediatric care.
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Search Strategy
We performed a literature review in PubMed limiting to
English language articles, with no beginning date and
search was last updated in July 2021. The search term was
“anti-Mullerian hormone” (MeSH term) comprising all
variations of AMH and MIS. We used filters for English
language and age (child: birth-18 years), and a total of 599
manuscripts including 41 review articles were identified.
We narrowed down the search further with filters for clinical studies and systematic reviews to 70 articles. The reference lists of the original and review articles were then
reviewed to ensure completeness.

Physiological Role of AMH
AMH is secreted as a 140kDa dimeric glycoprotein hormone structurally related to transforming growth factor
β and inhibin (6). It undergoes proteolytic cleavage and
generation of bioactive 25kDa C-terminal dimers that
bind to the AMH type 2 receptor (7-13). It is thought
that, in a similar manner to other members of the transforming growth factor β family, the ligand bound AMH
type 2 receptor phosphorylates the type 1 receptor [also
a serine/threonine kinase receptor, that belong to a class
of activin-like kinase (ALK2)] inducing signaling through

phosphorylation of intracellular Smad proteins, which then
translocate to the nucleus and modulate gene transcription
(14) (Fig. 1A and B). The AMH gene has been localized
to chromosome 19p13.3 (15), and its expression is tightly
regulated in Sertoli and granulosa cells specific to sex and
developmental stage (fetal, neonatal, pre-and postpubertal)
and regulated by SRY with activation of AMH by SOX-9
(16) and subsequent increase in AMH promoter activity
by transcription factors steroidogenic factor 1 (SF-1) (17),
GATA-4 (18,19), and WT-1 (20) and downregulation by
DAX-1 (20). In the testes, high follicle-stimulating (FSH)
levels activate AMH secretion (21), but androgens, specifically intratesticular testosterone, downregulates AMH
secretion acting through the androgen receptor (Fig. 1A)
but requires SF-1 binding to AMH promoter sites (22). In
the ovarian granulosa cells, AMH secretion appears to be
regulated by transcription factors SF1, FOXL2, FOG2, and
GATA-4 and stimulated by FSH and luteinizing hormone
(LH) (23-25).
In the fetal Sertoli cells, AMH expression was seen
starting around 8 weeks of gestation (26) during a short
window when Mullerian ducts are responsive to its effect
(27), leading to irreversible Mullerian duct regression by
the ninth week (28). AMH continues to be produced by the
fetal testes throughout gestation despite increase in testosterone since Sertoli cells in the fetus do not express androgen
receptors (29). Jost proposed that AMH may play a role in
the meiotic and mitotic arrest of germ cells (30), and others
have suggested roles for AMH in testicular descent, germ
cell maturation, and gonadal morphology, but these remain
inconclusive (31). After a transient decline postnatally,
AMH levels rise in infancy and continue to remain comparatively higher in males until they decline by stages 2 and
3 of puberty as intratesticular testosterone levels start to
rise (32). At this point, AMH levels in postpubertal males
are comparable and overlap with AMH levels in females
considerably although median AMH remains 2- to 3-fold
higher compared with females (33). Immunohistochemistry
has shown that the expression of AMH type 2 receptor parallels AMH in serum declining after puberty in males (34).
A paracrine effect of AMH was also postulated given findings that AMH pathway activation may directly suppress
the expression of steroidogenic enzymes in the Leydig cells
of the adult testes (35).
In contrast, AMH expression in fetal ovaries was detected around 23 weeks of gestation, with serum AMH detectable postnatally by 26 weeks of gestation (36). AMH
expression was highest in the granulosa cells of secondary,
preantral, and small antral cells (less than 4 mm in diameter)
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Anti-Mullerian hormone (AMH), also known as Mullerian
inhibiting substance (MIS), is a hormone produced exclusively in the gonads. Alfred Jost, a pioneering researcher
in the field of fetal endocrinology first proposed the existence of the “hormone inhibitrice” in the 1940s when
he demonstrated the regression of the “Mullerian ducts”
(paramesonephric ducts), anlagen to the uterus, Fallopian
tubes, cervix, and upper third of the vagina, in undifferentiated female rabbit embryos following surgical implants
of testicular tissue (1,2). Josso et al demonstrated that the
Sertoli cells secreted MIS, a glycoprotein (3) that was eventually purified, and coined the term “AMH” now widely
in use today, and Donahoe et al synthesized functional recombinant human MIS (4). In the decades that have followed, the sexually dimorphic functions of AMH have not
only played a part in the diagnosis of differences (originally
“disorders”) in sexual development (DSD) but has found
extensive clinical utility in female fertility and reproductive
health and its significance continues to evolve with the
finding of novel neuroendocrine regulatory actions of AMH
(5). In this mini-review, we examine the physiological role
of AMH and its clinical utility in pediatric patients.
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and significantly declines in larger antral follicles (6-8 mm)
(37). Data from rodent studies (38) and immunostaining
patterns in human ovaries (37) suggest that AMH may
suppress initial recruitment of primordial follicles and also
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Figure 1. Regulation of anti-Mullerian hormone (AMH) secretion and signaling. (A) Regulation of AMH secretion in males by developmental stage.
(B) Regulation of AMH secretion in females and its role in ovarian follicle maturation. Abbreviation: AR, Androgen receptor.
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modulate follicular sensitivity to FSH (39), regulating the
growth of follicles and the cyclic recruitment of the larger
antral follicles. AMH also downregulates the aromatase
activity in granulosa cells decreasing estradiol production
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Figure 1. Continued.

until follicular selection (40,41). AMH tends to be 35-fold
lower in females compared with males in infancy and remains stable through childhood and adolescence (42).
Recent longitudinal data suggest a slight rise in AMH by 7
to 9 years with a dip around the ages of 10 to 14 years correlating with the transition through puberty, rising again
by age 16 years to peak in young adulthood (43). AMH
then declines over the reproductive age proportionate to
the decline in the antral follicle pool and decreases rapidly
by menopause and, as such, is suggested as a marker of
ovarian aging (44).

Serum AMH Measurements
Enzyme-linked immunosorbent assays were first developed to measure AMH in the 1990s (45) but were not adequately sensitive to measure levels especially in females.
In 2000, an ultrasensitive assay was developed (46) with a
detection limit of 2 ng/mL [Immunotech (IOT), Marseille,
France] followed by a more sensitive assay with a detection limit of 6.3 pg/mL [Diagnostic Systems Laboratory
(DSL), Webster, TX, USA] (41). Since the calibrators and
antibodies were different, the DSL assay results for serum
AMH in women was 4.6-fold lower than the IOT assay
(47), invalidating comparisons between studies using these
2 different nonstandardized assays. A Gen II assay of AMH

(Beckman Coulter, Chaska, MN, USA) has been in use since
2010 (48), and normative data on serum AMH are depicted
in Figure 2 (49). Although calibrated to the IOT assay, several studies have raised concerns with regard to the Gen II
AMH assay, especially related to sample characteristics and
differences in calibration compared with newer immunoassays in the past few years (50). Hence, there is still a need
to establish assay-specific normative data in the absence of
an international reference standard.
AMH concentrations are age and sex-specific (49), rise
in early infancy starting 1 month after birth peaking around
6 months of age in male infants while they remain low in
female infants (Fig. 2). Throughout childhood, AMH concentrations are distinctly higher in males (almost 35-fold)
(51), so despite individual variability and a broad normal
range, it is easily discriminated from female norms (33)
(Fig. 2). In adolescence with progression through puberty,
the mean AMH levels decline in males and increase in females with considerable overlap (33,52).

Clinical Utility of AMH
AMH and Differences in Sexual Development
The process of sexual differentiation is a carefully orchestrated process with multiple regulatory elements impacting
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steps of differentiation. AMH was first described in the
context of dysregulated sexual differentiation, and the first
clinical utility was in the diagnosis of differences of sexual
development. While the presence of Mullerian duct derivatives reflects the lack of AMH secretion during the sixth
to tenth weeks of fetal life, the serum AMH measurements
after birth reflect not only Sertoli cell function in patients
with DSD but also serve as a biomarker of the relative influence of FSH and androgens (53). FSH increases Sertoli
cell mass and AMH secretion, but testosterone acting via
the androgen receptors in Sertoli cells postnatally suppresses AMH (22,54). So, AMH concentrations are directly
correlated to FSH but inversely to testosterone levels in
childhood and adolescence, in contrast to prenatal values.
AMH concentrations vary by pathology, genetic defect,
and developmental stage and are summarized in Table 1.
In 46,XY gonadal dysgenesis, the AMH concentrations are
proportionate to the presence of testicular tissue, typically
being low or undetectable in conditions affecting testicular
development (55). In Leydig cell hypoplasia, and androgen
synthetic defects, the AMH concentrations are typically
normal and may even be high during the minipuberty of
infancy due to a lack of the suppressive effect of androgens
(55,56). In 5-alpha reductase deficiency, characterized by
a high testosterone:dihydrotestosterone ratio, AMH was
in the lower range of normal (<−1 SD) since dihydrotestosterone is not required for suppression of AMH secretion (57). In androgen insensitivity syndrome, however,
the relatively high gonadotropins and lack of a functional

androgen receptor cause AMH levels to be inappropriately
high for the degree of testosterone in the serum (56). Recent
studies indicate that the hyperestrogenic state in complete
AIS may also play a role in AMH elevation (58). A study of
the testosterone response to human chorionic gonadotropin
(hCG) stimulation in prepubertal patients with 46,XY DSD
found that a normal serum AMH had a positive predictive
value of 84% for a normal post-hCG testosterone level, but
a low AMH was not useful in predicting a suboptimal testosterone response (59). Gonadal dysgenesis and ovotestes
were associated with mean AMH concentrations in between levels seen in anorchia and undescended testes (60).
In summary, AMH can be a useful tool for assessment of
Sertoli cell function in 46,XY DSD and can help distinguish
testicular dysgenesis from biosynthetic defects.
In 46,XX DSD, serum AMH above the female reference standards suggest the presence of testicular tissue
(as seen in ovotesticular or testicular DSD), which distinguishes these disorders from virilized female infants with
high extratesticular androgens (such as congenital adrenal
hyperplasia) (55) who have typical female AMH levels.
AMH in Klinefelter syndrome was found to be within
the normal reference range during minipuberty of infancy
and throughout childhood (61). The decline in AMH with
puberty was delayed in adolescents with Klinefelter syndrome although pubertal onset is still on time (62). This
has been attributed to a downregulation of AMH in these
affected individuals (63), as well as relatively low testosterone concentrations coupled with Sertoli cell destruction
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Figure 2. Reference ranges for serum anti-Mullerian hormone (AMH). Serum AMH in 1027 males (blue circles) and 926 females (red circles) is depicted
with blue and red lines depicting (median, +/−2 SD) reference ranges for males and females, respectively. Connecting grey lines represent longitudinal values in infancy. Age in years on the x-axis and serum AMH (pmol/L) measured on Immunotech (IOT) on the logarithmic y-axis. Comparative
data for Diagnostic Systems Laboratory (DSL) and Gen II assays were calculated as follows: AMH (IOT) pmol/L = 2.0 × AMH (DSL) μg/L × 7.14 pmol/μg
and AMH (IOT) pmol/L = 0.74 × AMH (Gen II) μg/L × 7.14 pmol/μg. This figure is reproduced from Johansen ML, et al (49). Copyright © 2013 Marie
Lindhardt Johansen et al. This is an open access article distributed under the Creative Commons Attribution License http://creativecommons.org/
licenses/by/3.0/ which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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Table 1. AMH and differences in sexual development

314 
The Journal of Clinical Endocrinology & Metabolism, 2022, Vol. 107, No. 2

Mixed gonadal dysgenesis

Abbreviations: AMH, anti-Mullerian hormone; FSH, follicle-stimulating hormone; LH, luteinizing hormone.

Ambiguous genitalia with +/− persistent unilat- AMH above female reference standards after
Variable but typically low testoseral/bilateral Mullerian structures
birth but decline in childhood
terone/estradiol and elevated
46,XX/46,XY Ovotestes or unilateral dysgenetic testes/contraFSH/LH at puberty
typically
lateral ovarian tissue
Variable, but typically low testosAMH above female reference standards after
45,X/46XY
Ambiguous or male external genitalia
terone for reference male for
birth typically, but variable and may decline
typically
Asymmetric gonadal dysgenesis, with dysgenetic
age
in childhood
testes/streak gonads
Mullerian structures variable and often absent
on testicular side
46,XX or
Ovotesticular DSD

Serum AMH
Phenotype
Karyotype
Pathology

Table 1. Continued
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and lack of meiotic germ cells. AMH levels in adults with
Klinefelter syndrome were lower than healthy males and
attributed to the testicular tissue and Sertoli cell destruction
seen in these individuals (62).
Isolated absence of AMH effect with normal testicular
Leydig cell function is seen in persistent Mullerian duct syndrome (PMDS), a rare autosomal recessive disorder caused
by loss of function mutations in the AMH gene (AMH deficiency) or the AMH type 2 receptor gene, AMHR2 (AMH
receptor insensitivity) detectable in nearly 88% of affected
individuals (64). PMDS is characterized by completely
virilized male external genitalia in 46,XY males and variable persistence of Mullerian structures, presenting with
the following phenotypes: (1) bilateral cryptorchidism and
testes in the pelvis attached to Fallopian tubes/uterus, (2)
unilateral cryptorchidism associated with a testis in the inguinal canal attached to the herniated uterus/Fallopian tube
(hernia uteri inguinalis), or (3) transverse testicular ectopia
(unique to PMDS, with bilateral testes and Mullerian
structures herniated into a single processus vaginalis) (64).
AMH gene mutations with a few exceptions, are associated
with an unstable protein and, hence, very low or undetectable serum AMH in prepubertal male patients compared
to a normal-for-age AMH in AMH receptor defects (65).
The AMH concentrations are not elevated in prepubertal
males with AMH receptor defects causing PMDS since the
testosterone and FSH concentrations are normal in these
patients. There is no reported clinical phenotype in females
with AMH gene or AMHR2 receptor mutations although
there is some speculation for possible early menopause in
these individuals based on animal studies (64).

AMH and Cryptorchidism
In infants with male external genitalia and cryptorchidism,
the detection of AMH secreted from the Sertoli cells can
help differentiate between absent gonads (anorchia with
undetectable AMH) and undescended testicles with intact Sertoli cell function. In patients with cryptorchidism
without microphallus or genital ambiguity, AMH demonstrated 98% sensitivity and 91% specificity for the identification of testicular tissue (60,66). AMH was low or
absent in nearly half of the patients with isolated cryptorchidism, and the number increased to 61% in the presence of cryptorchidism and microphallus (67). In addition,
a low AMH was seen in 74% with bilateral nonpalpable
gonads and 35% of those with gonads palpable in the inguinal region reflective of diminished Sertoli cell function
(67). Additional studies have also shown lower AMH (and
inhibin B values) compared to normative data in 2-yearold male children with cryptorchidism, suggesting a functional defect of Sertoli cells in this condition (68). In a large
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AMH and Pubertal Disorders
Low AMH is also characteristic of prepubertal males with
hypogonadotropic (central) hypogonadism who have diminished Sertoli cell number and function due to FSH deficiency and has been shown to be low in hypogonadotropic
hypogonadism due to multiple pituitary hormone deficiency in infants (70). Inhibin B is often a useful adjunct
that parallels AMH secretion as well, and basal inhibin
B had a higher discriminatory value for distinguishing
hypogonadotropic hypogonadism from constitutional
delay of growth and puberty (71). During puberty, AMH is
low for Tanner stage (lack of FSH effect) and high for age
(lack of testosterone effect) (72). Further, treatment with
combined recombinant FSH and hCG lowers AMH during
pubertal induction in hypogonadotropic hypogonadism,
but testosterone therapy for pubertal induction does not
appear to lower AMH (73). This has been attributed to
the LH-driven rise in intratesticular testosterone, which
suppresses AMH and overshadows the stimulating effect
of FSH on AMH during combination therapy, whereas
intratesticular testosterone levels are not adequately raised
by exogenous testosterone therapy alone (73,74).
In isolated Leydig cell disorders, AMH was normal or
high (increased FSH effect but lack of testosterone effect)
(75). Precocious puberty in males including central precocious puberty and gonadotropin-independent forms
such as familial male limited precocious puberty were associated with low AMH secretion for age due to rise in
intratesticular testosterone (76). Gonadotropin-releasing
hormone (GnRH) analogue therapy normalizes AMH to
prepubertal values, suggesting that the Sertoli cell maturation in early puberty may be reversible and AMH could
potentially serve as an additional tool for diagnosis of

precocious puberty and treatment efficacy (77), although
not of routine clinical utility compared to LH/testosterone.
In females, AMH was normal in most patients with acquired multiple pituitary hormone deficiency but low in severe congenital hypopituitarism reflective of gonadotropin
deficiency (78). AMH has been shown to be lower in premature thelarche in females ages 1 to 3 years and negatively
correlated with FSH compared with age-matched controls
(79). In girls with precocious puberty, AMH levels did not
differ from healthy age-matched controls at baseline but
were suppressed compared to the pretreatment levels with
GnRH analogue therapy and returned to pretreatment
levels 6 months after discontinuation of treatment (80).
The authors speculated that the suppression of AMH was
consistent with gonadotropin-dependence of AMH secretion, but the normal AMH levels and negative correlation
with FSH at baseline were due to an individual set point for
the pituitary-gonadal feedback loop (80). Regardless, there
does not appear to be any clinical utility to routine monitoring of AMH in the management of precocious puberty
in female children.

AMH as a Marker of Granulosa Cell Tumors
Granulosa cell tumors (GCTs), the most common subtype
of ovarian sex cord-stromal tumors, represent 2% to 5%
of all ovarian cancers (81). GCTs are divided histologically
into juvenile GCTs, occurring primarily in children and
young adults, and adult GCTs, occurring typically in adult
women. Signs of excessive estrogen secretion such as precocious puberty in a prepubertal child or menstrual irregularities including hypermenorrhea in a postmenarchal
adolescent in the presence of an adnexal mass can lead to
the diagnosis of GCT. However, making an accurate preoperative diagnosis remains difficult. These tumors secrete
estrogen, inhibin B, and AMH. An elevation in AMH level
has been reported in both juvenile and adult GCTs (8284). AMH can be used as a marker of treatment efficacy
and tumor progression and recurrence and correlates with
tumor mass as determined by radiology or pathology (8486). In a recent meta-analysis evaluating the performance
of AMH in the diagnosis of GCT, the pooled sensitivity
was reported as 89% with a pooled specificity of 93% (87).
However, negative testing does not rule out GCTs, and there
are reported cases of discrepancy between inhibin B and
AMH levels in patients with progressive GCT (88). Given
the possibility of false negatives, measuring both AMH and
inhibin may improve the detection of GCT.

AMH and Polycystic Ovary Syndrome
Polycystic ovarian syndrome (PCOS) is the most common
cause of chronic anovulation and hyperandrogenism in
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cohort of males with cryptorchidism, AMH was shown to
be significantly lower in those with bilateral cryptorchidism
compared with unilateral cryptorchidism and controls; abnormally low AMH (<3%) was seen in 36.5% of patients
with bilateral cryptorchidism between the ages of 6 months
and 2 years (69). In pooled data of the studies by Lee et al
(60), normal AMH was 100% predictive of the presence
of testes while a measurable but low value was predictive
86% of the time, with an unmeasurable AMH being predictive of absent testicular tissue (anorchia) 94% of the
time. One exception to this would be patients with AMHnegative PMDS due to AMH gene mutations, who also
have undetectable AMH but nondescent of testes due to
the presence of Mullerian-derived structures affecting descent. A pelvic ultrasound to detect Mullerian structures can
distinguish this condition from anorchia due to testicular
regression syndrome where Mullerian derivatives are absent (53).
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AMH as a Marker of Ovarian Reserve/Fertility
Ovarian reserve, as defined by American Society for
Reproductive Medicine, represents the number of oocytes remaining in the ovary or oocyte quantity (oocyte number) (100). Ovarian reserve tests include both
ultrasound imaging and biochemical tests. Antral follicle
count (AFC), a marker of ovarian reserve, is traditionally
performed in the early follicular phase by transvaginal
ultrasound, which precludes its use in prepubertal children as well as postmenarchal adolescents who do not
tolerate transvaginal imaging. Although transabdominal

AFC measurements have been performed in both prepubertal and pubertal children, AMH was only moderately correlated to AFC in premenarchal girls (101). AMH
is a sensitive biochemical marker of ovarian reserve and
may be more sensitive when compared to early follicular
phase FSH and estradiol levels (102). The ideal timing
of AMH measurement depends on whether serum AMH
levels vary throughout the follicular and luteal phases of
the menstrual cycle. Numerous studies have investigated
AMH variations during the menstrual cycle, and some
have reported only mild intra- and intercycle fluctuations
of AMH secretion (103-105), while others have reported
a peak AMH level in the mid-follicular phase with a subsequent decrease in the luteal phase (106,107). However,
these fluctuations are not large enough to warrant a recommendation of timed AMH measurement on specific
menstrual cycle days or phases (107,108). Although
AMH has the ability to predict ovarian responsiveness
to gonadotropin stimulation and oocyte yield in assisted
reproductive technologies, it is a poor predictor of pregnancy and live birth rates (100).
AMH is expressed by granulosa cells of growing follicles
after recruitment of primordial follicles from the resting
pool and expression increases until the large preantral and
small antral follicular stage (109,110) (Fig. 1B). AMH expression is lost in the atretic follicle as well as corpus lutea.
With age, AMH decreases, and serum AMH levels correlate
strongly with the decrease in size of the antral follicle pool
(111,112). There is no marker that can directly measure
the number of primordial follicles. However, the number of
growing follicles recruited from the primordial follicle pool
reflect the number of primordial follicles. As a marker for
the number of growing follicles, AMH is used as a proxy
for the number of primordial follicles and the quantitative
aspect of the ovarian reserve in adults (113). In prepubertal
children, however, ovarian follicles remain in a quiescent
state after the minipuberty of infancy. AMH is not expressed by primordial or small preantral follicles and,
prior to the onset of puberty, may correlate poorly with
ovarian reserve in children. In vitro evaluation of ovarian
tissue in children undergoing ovarian tissue cryopreservation (OTC) prior to gonadotoxic therapies due to malignant diseases that do not affect ovarian reserve parameter
revealed high follicle density despite low AMH levels (114).
In addition, studies reporting intervals for AMH in children
demonstrated wide variations in AMH in healthy girls ages
1 to 12 years (42,115). Despite these limitations, AMH
has been proposed as a potential biomarker of ovarian
reserve in childhood to determine possible candidates for
fertility preservation and the timing of such interventions
in children and adolescents at risk of primary ovarian
insufficiency (POI).
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young women, with a prevalence of 8% to 13% (89,90).
The International Guideline for the Assessment and
Management of PCOS endorses the Rotterdam PCOS diagnostic criteria in adults (2 of oligo- or anovulation, clinical
and/or biochemical hyperandrogenism, or polycystic ovaries
on ultrasound), after exclusion of related disorders. In adolescents, both oligoanovulation and hyperandrogenism are
required, with ultrasound not recommended for diagnosis
(91). Serum AMH levels are consistently higher in women
with PCOS (92,93). Abnormally slow growth of primary
follicles results in an elevated number of AMH-producing
cells. There also appears to be an increased production
of AMH per follicle as evidenced by a mean AMH level
4× higher in granulosa cells from ovulatory PCOS and
75× higher in granulosa cells of anovulatory PCOS (94).
Adolescent daughters of women affected by PCOS have
higher AMH levels compared to girls with obesity (95,96).
Higher AMH levels in adolescent daughters of women affected by PCOS is associated with menstrual cycle irregularities and higher ovarian volumes, suggesting differences in
ovarian folliculogenesis in adolescents at risk of developing
PCOS (97). Currently, there is no consensus on an AMH
threshold for the diagnosis of PCOS. AMH levels have been
reported to be a more reliable marker of polycystic ovarian
morphology (PCOM) than follicle number with an AMH
threshold of 35 pmol/L (5ng/mL) suggested as a possible
inclusion in the diagnostic criteria of PCOS (98). Some authors have proposed increased AMH levels as an adjunct in
the diagnosis of PCOS in adolescents and reported that an
AMH level > 3.4ng/mL best distinguishes adolescents with
PCOS from controls (99). The International Guideline for
the Assessment and Management of PCOS does not recommend the use of serum AMH as an alternative to the detection of PCOM or as a single test for the diagnosis of PCOS.
However, there is mention that with improved standardization of assays and established cutoff levels or thresholds
based on large-scale validation in populations of different
ages and ethnicities, AMH assays would be more accurate
in the detection of PCOM (91).
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even autocrine effects (5). Loss-of-function heterozygous
mutations in AMH and AMHR2 genes were identified in
congenital hypogonadotropic hypogonadism, suggesting
a possible role of AMH signaling in the development, migration, and function of GnRH neurons (131). Paracrine
actions of AMH in adult ovaries regulating follicular recruitment and in adult testes regulating steroidogenesis and
Leydig cell/germ cell maturation, as well as a postulated
role for AMH in the prenatal reprogramming of neuroendocrine pathways for pathogenesis of PCOS in the offspring, suggest that our understanding of this multifaceted
hormone and its clinical utility continues to evolve (5,132).
Therapeutic applications of AMH for treating ovarian and
endometrial cancer and PCOS, preserving fertility, and
delaying ovarian aging (133) hold promise but will require standardization of current assays and development of
AMH analogues (134).

Future Directions

Additional Information

The clinical utility of AMH has continued to expand with
the understanding of sexual differentiation and the elucidation of the molecular basis of AMH action. Originally,
AMH expression was thought to be limited to the gonads,
but recent studies not only demonstrate AMH and AMHR2
expression in different neurons but also confirm AMH
actions at different levels of the hypothalamic-pituitarygonadal axis to increase the activity of GnRH neurons
and the sensitivity of gonadotropes to GnRH signaling,
LH pulsatility (130), modulating GnRH/LH/FSH secretion
through possibly endocrine (circulating gonadal AMH), or
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Conclusions
AMH is a valuable tool in the care of pediatric patients with
diverse conditions affecting gonadal development and function. The interpretation of serum AMH should be informed
by assay-specific normative data accounting for age/sex and
pubertal stage. In conjunction with gonadotropins and testosterone, AMH can be a useful diagnostic marker of Sertoli cell
mass and function in males. Although widely used as a biochemical marker of ovarian reserve in females, the predictive
value of AMH in prepubertal females for fertility outcomes
needs further study. Assay standardization and widespread
availability will further enhance its utility in clinical practice.
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Turner syndrome (TS), caused by X-chromosome anomalies with or without mosaicism, is characterized by an increased risk of POI due to accelerated ovarian follicular
apoptosis before and/or after puberty (116). In adolescents
and young adults with TS, higher AMH levels are associated with spontaneous puberty and ongoing ovarian function (42,115) and negatively correlated with FSH, LH and
45,X karyotype (117). In addition, AMH < 4 pmol/L has
been reported as predictive of absent puberty in prepubertal
girls and POI in adolescents and adult patients (118). Care
should be taken in the generalization of these results, however, as the evaluation of AMH as a predictor of spontaneous puberty was based only on 15 patients before pubertal
onset (5 with spontaneous puberty and 10 with puberty
induced by hormone replacement therapy). Some investigators have proposed guidelines for performing OTC
based on serum AMH levels in prepubertal girls with TS
(119). However, the available limited data on OTC in girls
<12 years with TS do not allow for meaningful clinical predictions of the feasibility of OTC and ovarian follicular
density based on AMH levels alone (120-125).
As the number of childhood cancer survivors increase, attention to long-term adverse health effects outcomes including
future fertility has been identified as a major concern of patients and their families (126). Risk factors for POI include age
at diagnosis, abdominal/pelvic radiation therapy, and exposure
to alkylating agents (127). In a small study of 16 postmenarchal
adolescents undergoing chemotherapy for oncology diagnoses
(leukemia, lymphoma, and sarcoma), 94% showed a decline
in mean AMH levels at 6 months postdiagnosis, but 80%
showed at least some recovery of AMH by 18 to 24 months
(128). Longitudinal follow-up in female childhood cancer survivors showed that although AMH levels were significantly
low compared to age-matched controls, in women with sustained ovarian function (AMH > 1.0µg/L), the decline in
AMH is similar to that in the normal population (129). In
adolescents requiring treatment with chemotherapy, the predictive value of AMH as it relates to spontaneous pregnancy
requires further longitudinal studies.
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